Interferon beta drugs have become a cornerstone therapy in the treatment of multiple sclerosis (MS), a chronic autoimmune condition that attacks the central nervous system. MS leads to demyelination, where the protective sheath around nerve fibers deteriorates, causing symptoms such as muscle weakness, coordination issues, and cognitive decline. Interferon beta works by modulating the immune system, reducing inflammation, and limiting the frequency and severity of MS relapses.
Since their introduction in the 1990s, interferon beta-1a and interferon beta-1b have significantly improved the management of relapsing-remitting multiple sclerosis (RRMS). These drugs help suppress abnormal immune activity and maintain the integrity of the blood-brain barrier, slowing disease progression. Studies have shown that patients receiving interferon beta experience fewer relapses and improved neurological outcomes compared to untreated individuals.
New formulations and delivery mechanisms have enhanced patient compliance. Pegylated interferon beta offers extended dosing intervals, reducing the frequency of injections. Additionally, research into oral…